Creative Enzymes, a global enzyme technology service provider, has launched an AI-integrated biocatalysis platform designed to accelerate enzyme development by merging computational enzyme engineering with practical process development. The platform addresses a critical gap in biomanufacturing: the slow pace of enzyme catalyst development, which often hinders iterative product development. By leveraging artificial intelligence, the platform predicts enzyme candidates, designs enzymes constrained by process parameters, and anticipates process performance using key molecular features, thereby reducing the need for extensive experimental testing and lowering R&D costs.
The platform's capabilities are delivered through three specialized service modules. The AI-Driven Biocatalysis Solutions module offers an end-to-end workflow from target reaction analysis to scale-up characterization, encompassing computational screening, process optimization, and scale-up evaluation. This structured approach shortens the design-build-test-learn cycle from the conventional 12–24 months to just 8–12 months for moderately complex targets.
The AI-Driven Industrial Biocatalysis module focuses on bridging lab-scale performance and commercial production, addressing substrate concentration optimization, cofactor regeneration, immobilization, and integration of process analytical technology. The goal is to improve the industrial workflow around catalytic processes.
The AI-Driven Green Biocatalysis module provides sustainability-focused solutions, leveraging enzymatic reactions that occur in aqueous media at room temperature, minimizing organic solvents and emissions, and reducing byproduct formation. AI-guided development amplifies these environmental benefits.
The platform's effectiveness was demonstrated in a case study on transaminase engineering, where researchers developed a 6D protein engineering framework combining interaction energy, solvent effects, and 1.39 million structural fragments. Five AI-selected transaminase variants with nine mutations each showed high solubility and catalytic stability at 7-liter fermentation scale, converting prochiral ketones to sitagliptin with enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up production.
AI biocatalysis is currently making significant impacts in pharmaceuticals, particularly in asymmetric synthesis of chiral intermediates and replacing hazardous reagents. Agrochemicals and food industries are also adopting these technologies to improve toxicology profiles and enable cleaner labels, while fine chemicals and personal care sectors are exploring high-value conversions and more sustainable processes.
